Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iopofosine I 131 - Cellectar Biosciences

Drug Profile

Iopofosine I 131 - Cellectar Biosciences

Alternative Names: (131)I-CLR1404; 131-I-NM404; 131I-CLR1404; CLR 1404 I-131; CLR-131; HOT; I-131-CLR1404; NM-404

Latest Information Update: 10 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan Medical School
  • Developer Cellectar Biosciences; University of Wisconsin-Madison
  • Class Antineoplastics; Drug conjugates; Iodine radioisotopes; Phospholipid ethers; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rhabdomyosarcoma; Neuroblastoma; Osteosarcoma; Multiple myeloma; Ewing's sarcoma; Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haematological malignancies; Multiple myeloma; Waldenstrom's macroglobulinaemia
  • Phase I/II Non-small cell lung cancer
  • Phase I Brain cancer; Glioma; Head and neck cancer; Lymphoma; Solid tumours

Most Recent Events

  • 27 Mar 2024 Cellectar Biosciences announces intention to submit NDA for Waldenstrom’s macroglobulinemia in March 2024
  • 27 Mar 2024 Cellectar Biosciences plans to request accelerated approval for Waldenstrom’s macroglobulinemia
  • 27 Mar 2024 Efficacy data from a phase I trial in Head and neck cancer released by Cellectar Biosciences
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top